Literature DB >> 25364519

Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence.

Chanyeong Park1, In Jae Lee1, Seung Hun Jang1, Jae Woong Lee1.   

Abstract

BACKGROUND: Although surgery is potentially curative treatment for non-small cell lung cancer (NSCLC), the risk of postoperative disease recurrence is still high. This study was conducted to assess the factors associated with postoperative tumor recurrence in patients who underwent curative surgery for NSCLC.
METHODS: One hundred seventy-one patients who underwent curative surgery for NSCLC were included in this study. Clinicopathological factors of histologic type, pathologic TNM stage, T stage, N stage, lymphovascular invasion (LVI), perineural invasion (PNI), surgical procedure, adjuvant chemotherapy and adjuvant radiotherapy were investigated. Gender, age, and clinicopathologic factors were included in univariate and multivariate analyses using the Kaplan-Meier method and Cox proportional hazards model, respectively. Mann-Whitney U and Kruskal-Wallis tests were used to investigate the significance of differences in recurrence-free interval (RFI) according to clinicopathological factors.
RESULTS: Median RFI was 20 months. Univariate and multivariate analyses for overall recurrence identified T stage, N stage, and LVI as significant factors (P=0.045, 0.044, and <0.001, respectively). Pathologic stage (P=0.005) was the only factor that was significantly associated with locoregional recurrence. T stage (P=0.040) and LVI (P<0.001) were significantly associated with distant recurrence. The difference in 2-year freedom from recurrence between LVI positive and negative groups was significant (14.9% vs. 44.6%, P<0.001). LVI was the only factor that was significantly associated with a shortened mean RFI (P<0.001).
CONCLUSIONS: LVI had a significant effect on both overall and distant recurrence rates as well as on early tumor recurrence after curative surgery for NSCLC.

Entities:  

Keywords:  Thorax; lung; metastases; pathology; surgery

Year:  2014        PMID: 25364519      PMCID: PMC4215149          DOI: 10.3978/j.issn.2072-1439.2014.09.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

1.  Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.

Authors:  Kristin A Higgins; Junzo P Chino; Neal Ready; Thomas A D'Amico; Mark F Berry; Thomas Sporn; Jessamy Boyd; Chris R Kelsey
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

2.  Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials.

Authors:  Y Ichinose; H Kato; T Koike; R Tsuchiya; T Fujisawa; N Shimizu; Y Watanabe; T Mitsudomi; M Yoshimura
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

3.  Prognostic impact of vascular and lymphovascular invasion in early lung cancer.

Authors:  Bassel S Al-Alao; Kathy Gately; Siobhan Nicholson; Eilis McGovern; Vincent K Young; Kenneth J O'Byrne
Journal:  Asian Cardiovasc Thorac Ann       Date:  2013-09-04

Review 4.  Treatment of recurrent disease in lung cancer.

Authors:  Frank B Zimmermann; Michael Molls; Branislav Jeremic
Journal:  Semin Surg Oncol       Date:  2003

5.  Risk factors for recurrence after lung cancer resection as estimated using the survival tree method.

Authors:  Shigeki Sawada; Natsumi Yamashita; Hiroshi Suehisa; Motohiro Yamashita
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

6.  Radiotherapy for locoregional recurrent tumors after resection of non-small cell lung cancer.

Authors:  Y Kagami; M Nishio; N Narimatsu; M Mjoujin; T Sakurai; M Hareyama; A Saito
Journal:  Lung Cancer       Date:  1998-04       Impact factor: 5.705

7.  Accuracy and prognostic impact of a vessel invasion grading system for stage IA non-small cell lung cancer.

Authors:  Satoshi Hashizume; Takeshi Nagayasu; Tomayoshi Hayashi; Shigekazu Hidaka; Tomoshi Tsuchiya; Tsutomu Tagawa; Naoya Yamasaki; Katsuro Furukawa; Keitaro Matsumoto; Takuro Miyazaki
Journal:  Lung Cancer       Date:  2009-01-21       Impact factor: 5.705

Review 8.  Follow-up and surveillance of the lung cancer patient following curative-intent therapy.

Authors:  Gene L Colice; Jeffrey Rubins; Michael Unger
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

9.  Stage II-IV lung cancer cases with lymphovascular invasion relapse within 2 years after surgery.

Authors:  Satoshi Shiono; Naoki Kanauchi; Naoki Yanagawa; Masami Abiko; Toru Sato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-11-02

10.  Imaging of recurrent lung cancer.

Authors:  Naama R Bogot; Leslie E Quint
Journal:  Cancer Imaging       Date:  2004-03-04       Impact factor: 3.909

View more
  13 in total

1.  Intratumoral lymph vessel invasion as a predictive risk factor for nodal metastasis in non-small cell lung cancer: should L-1 status obligate adjuvant chemotherapy?

Authors:  Kimberly J Song; Raja M Flores
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Prognosis After Sublobar Resection of Small-sized Non-small Cell Lung Cancer with Visceral Pleural or Lymphovascular Invasion.

Authors:  Youngkyu Moon; Kyo Young Lee; Jae Kil Park
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

3.  Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma.

Authors:  Pei Nie; Guangjie Yang; Ning Wang; Lei Yan; Wenjie Miao; Yanli Duan; Yanli Wang; Aidi Gong; Yujun Zhao; Jie Wu; Chuantao Zhang; Maolong Wang; Jingjing Cui; Mingming Yu; Dacheng Li; Yanqin Sun; Yangyang Wang; Zhenguang Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-25       Impact factor: 9.236

4.  Clinical Characteristics and Outcome of Pathologic N0 Non-small Cell Lung Cancer Patients With False Positive Mediastinal Lymph Node Metastasis on FDG PET-CT.

Authors:  Kyu Yean Kim; Hye Lim Park; Hye Seon Kang; Hwa Young Lee; Ie Ryung Yoo; Sang Haak Lee; Chang Dong Yeo
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

5.  Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma.

Authors:  Qiwen Li; Li Ma; Bo Qiu; Yuzhi Wen; Wenhua Liang; Wanming Hu; Naibin Chen; Tian Zhang; Shuangbing Xu; Lingjuan Chen; Minzhang Guo; Yi Zhao; Songran Liu; Jinyu Guo; Junye Wang; Siyu Wang; Xin Wang; Qingsong Pang; Hao Long; Hui Liu
Journal:  Curr Oncol       Date:  2021-04-07       Impact factor: 3.677

6.  Autonomic nervous infiltration positively correlates with pathological risk grading and poor prognosis in patients with lung adenocarcinoma.

Authors:  Jing-Xin Shao; Bo Wang; Yi-Nan Yao; Zhi-Jie Pan; Qian Shen; Jian-Ying Zhou
Journal:  Thorac Cancer       Date:  2016-07-12       Impact factor: 3.500

7.  LncRNA TP73-AS1 interacted with miR-141-3p to promote the proliferation of non-small cell lung cancer.

Authors:  Xinfa Liu; Mingming Wang; Yanzhi Cui
Journal:  Arch Med Sci       Date:  2019-07-22       Impact factor: 3.318

8.  MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.

Authors:  Guido Biasco; Elisa Giovannetti; Ingrid Garajová; Niccola Funel; Michelangelo Fiorentino; Valentina Agostini; Manuela Ferracin; Massimo Negrini; Giovanni Luca Frassineti; Giampaolo Gavelli; Adam Enver Frampton
Journal:  Clin Epigenetics       Date:  2015-12-16       Impact factor: 6.551

9.  miR-32 inhibits proliferation, epithelial-mesenchymal transition, and metastasis by targeting TWIST1 in non-small-cell lung cancer cells.

Authors:  Lei Li; Dapeng Wu
Journal:  Onco Targets Ther       Date:  2016-03-14       Impact factor: 4.147

10.  Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection.

Authors:  Ching-Yang Wu; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ying-Huang Tsai
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.